Sanofi Finalizes Acquisition of Dynavax in a $1.31B Tender Offer
DYNAVAX TECHNOLOGIES CORP
Filing Summary
Sanofi Finalizes Acquisition of Dynavax in a $1.31B Tender Offer
Company: Dynavax Technologies Corp Form: SC TO-T/A | Filed: 2026-02-10 Significance: High
Acquirer: Sanofi Relationship: Offeror
Transaction: • Type: Tender Offer Purchase • Shares Tendered: 84,680,752 • Price: $15.50 • Value: $1,312,551,656 • Ownership After: ~73.92% (leading to full merger)
Key Insight: Sanofi has successfully completed its tender offer, acquiring a controlling stake in Dynavax. This action will trigger a full merger and the delisting of Dynavax shares from the NASDAQ.
Market Context: This filing confirms the final results of the tender offer, marking the end of Dynavax as a publicly traded entity and its integration into Sanofi.
Comprehensive Analysis
SEC Filing Analysis: Dynavax Technologies Corp
Executive Summary
- Trading Significance: High
- Key Takeaway: Sanofi has successfully acquired a controlling stake of approximately 73.92% in Dynavax Technologies Corp through a tender offer valued at over $1.31 billion, paving the way for a full merger and delisting of Dynavax stock.
- Market Impact: This is a definitive change-of-control event, concluding Dynavax's tenure as an independent public company.
Company Information
| Field | Value |
|---|---|
| Company | Dynavax Technologies Corp |
| Ticker Symbol | DVAX (Note: Not in filing, but publicly known; will be delisted) |
| CIK | 0001029142 |
| Industry | Pharmaceutical Preparations |
Acquirer Information
| Field | Value |
|---|---|
| Name | Sanofi |
| CIK | 0001121404 |
| Title/Position | Not Applicable |
| Relationship | Offeror / Acquirer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | SC TO-T/A |
| Transaction Date | 2026-02-09 |
| Transaction Code | Not Applicable (Tender Offer) |
| Security Type | Common Stock, Par Value $0.001 Per Share |
| Shares Involved | 84,680,752 |
| Price Per Share | $15.50 |
| Total Value | $1,312,551,656 |
| Shares Owned After | Not specified, but total holding represents ~73.92% of outstanding shares |
| Ownership Type | Indirect (via Samba Merger Sub, Inc.) |
Financial Impact Assessment
Transaction Materiality
Note: The provided market data was for the acquirer (Sanofi). The following analysis is based on data derived from the filing for the target company (Dynavax) for accurate context.
| Metric | Value |
|---|---|
| Transaction Value | $1,312,551,656 |
| Estimated Target Market Cap | ~$1.78 Billion (based on offer price and implied shares outstanding) |
| % of Market Cap | ~73.9% |
| Shares Transacted | 84,680,752 |
| % of Shares Outstanding | ~73.9% (of total shares outstanding, based on filing data) |
| Post-Transaction Ownership | ~73.92% of outstanding shares |
| Materiality Assessment | Highly Significant |
Impact Evaluation
- Market Cap Context: The transaction value represents a complete buyout of Dynavax, a multi-billion dollar entity. This is not an insider trade but a full corporate acquisition.
- Ownership Concentration: Sanofi, through its subsidiary, has moved from a potential suitor to the controlling majority shareholder, enabling it to execute a short-form merger without a stockholder vote.
- Dilution Impact: Not applicable. This is an acquisition of existing shares, not an issuance of new ones. The event is terminal for public shareholders, who will be cashed out.
- Transaction Significance: As a change-of-control transaction representing the vast majority of the company's equity and market value, the significance is maximal.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: This filing confirms the results of the tender offer. For remaining Dynavax shareholders, their shares will be converted to cash at the $15.50 offer price upon the merger's completion. Trading will cease, and the stock will be delisted, ending its public market journey.
Volume & Sentiment
- Expected Volume Impact: Trading volume will cease upon delisting.
- Sentiment Indicator: Neutral. The event is a finalized acquisition, not a speculative market event. The outcome is now certain for shareholders.
Investment Insights
Positive Market Indicators
- The successful tender offer indicates strong shareholder acceptance of the $15.50 per share valuation.
- For Sanofi, this represents a strategic acquisition to bolster its portfolio.
Risk Factors
- All risks are now moot for Dynavax public shareholders, as the company is being acquired and they will be cashed out.
Key Takeaways
- Acquisition Complete: Sanofi's tender offer for Dynavax was successful, with 84,680,752 shares tendered.
- Change of Control: Sanofi now controls ~73.92% of Dynavax, sufficient to proceed with a merger and take the company private.
- Delisting Imminent: Dynavax shares will be delisted from the NASDAQ Global Select Market, and shareholders not part of the tender will receive cash for their shares.
Additional Context
Transaction Notes
- This filing is Amendment No. 3 to the original Schedule TO, serving as the final amendment reporting the results of the tender offer.
- The offer expired at one minute following 11:59 P.M., Eastern Time, on February 9, 2026.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is AI-generated from public SEC filings and may contain errors. It is for informational and educational purposes only and is not investment, legal, or tax advice.
The Filing Fool is not a registered investment adviser, broker-dealer, or financial planner. Nothing here is a recommendation or solicitation to buy, sell, or hold any security.
Always do your own due diligence and consult a licensed professional.
